Virtual Medicinal Product (VMP) - Rozanolixizumab 560mg/4ml solution for infusion vials
Name Details
| Name | Start Date | End Date | |
|---|---|---|---|
| Name | Current Name Rozanolixizumab 560mg/4ml solution for infusion vials | Start Date 27-11-2024 | End Date |
Unit Dose & Form Information
- DF Indicator
- Discrete
- UDFS Indicator
- 4.0
- UDFS UOM
- ml
- Unit Dose UOM
- vial
Summary
- Prescribing Status
- Valid as a prescribable product
- Controlled Drug Category
- No Controlled Drug Status
- Route
- Subcutaneous
- Form
- Solution for infusion
- Ontology Form/Route
- solutioninfusion.subcutaneous
- Name Basis
- rINN - Recommended International Non-proprietary
Codes
- ATC Code
- L04AG16
- BNF Codes
-
- BNF code 08020400
| Code | Start Date | End Date |
|---|---|---|
| 44108411000001109 | 27-11-2024 |
VMP Ingredients
| Name | Basis of Strength Description | BOSS | Strength and UOM (Nmr) | Strength and UOM (Dmr) |
|---|---|---|---|---|
| Rozanolixizumab | Based on Ingredient Substance | 140 mg | 1 ml |
Name
Rozanolixizumab
Basis of strength description
Based on Ingredient Substance
BOSS
Strength and UOM (Nmr)
140.0
Strength and UOM (Dmr)
1.0
Parent Products
-
VTMRozanolixizumab
-
VMP(Current) Rozanolixizumab 560mg/4ml solution f...
-
AMP
-
-
Virtual Medicinal Product Pack (VMPP) Information
| Pack Size | Drug Tariff Price | Drug Tariff Payment Category |
|---|---|---|
| 1 vial |